NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study

Henrik Rudolf, Andreas Mügge, Hans J. Trampisch, Hubert Scharnagl, W. März, Kaffer Kara

Department for Medical Informatics, Biometry and Epidemiology, Ruhr-University Bochum, Bochum, Germany
Cardiovascular Center, St. Josef Hospital Bochum, Ruhr-University Bochum, Germany
Clinical Institute of Medical and Clinical Laboratory Diagnostics, Medical University of Graz, Graz, Austria
Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim and Augsburg, Germany
Medical Faculty Mannheim, University of Heidelberg, Germany

Article history:
Received 29 March 2020
Received in revised form 15 May 2020
Accepted 28 May 2020

Keywords:
Biomarker
Prevention
Natriuretic peptides
Primary care
Cardiovascular mortality

Abstract

Background: Beside their role in the diagnosis of heart failure in symptomatic patients with dyspnea, natriuretic peptides have been suggested to improve risk prediction of cardiac events and mortality in asymptomatic cohorts. We aimed to evaluate the prognostic value of NT-proBNP for cardiovascular and all-cause mortality above traditional risk factors in a prospective cohort study of unselected elderly patients in a representative primary care setting.

Methods: We followed 6382 patients of the getABI-study for 7 years. Associations of NT-proBNP levels (≤125, 125–300, >300 pg/ml for all) with all-cause and cardiovascular mortality were assessed using cox regression analysis.

Results: The incidence of all-cause and cardiovascular mortality was higher in subjects with higher levels of NT-proBNP (all-cause mortality/cardiovascular mortality: 35.4%/6% for NT-proBNP > 300 pg/ml; 16.2%/40% for NT-proBNP 125–300 pg/ml vs. 11.4%/4% for NT-proBNP ≤125 pg/ml. Participants with a NT-proBNP levels > 300 pg/ml had increased incidence of hard endpoint (hazard ratio (HR) (95% confidence interval (CI)): 3.62 (3.15–4.17) for all-cause mortality, and 6.38 (4.84–8.41) for cardiovascular mortality). These associations remained after adjustment for traditional risk factors and cardiac medications and diseases (HR = 2.64 (2.26–3.08) for all-cause mortality, and HR = 3.93 (2.90–5.32) for cardiovascular mortality).

Conclusion: Our results show strong associations of higher NT-proBNP levels with cardiovascular and all-cause mortality in an unselected, large population of elderly patients in the primary care setting independent of traditional risk factors indicating that NT-proBNP can help identifying subjects at high risk for cardiac events.

Corresponding author at: Cardiovascular Center, AKH Hagen, Grünstr. 35, 58095 Hagen, Germany.
E-mail address: Kaffer.Kara@ruhr-uni-bochum.de (K. Kara).
1 Equal contribution.
2 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
3 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
4 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
5 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
6 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
7 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

1. Introduction

Cardiac risk stratification detecting silent cardiac damage remains a challenge in modern medicine. B-type natriuretic peptide (BNP) and N-terminal pro BNP (NT-proBNP) are secreted from cardiac myocytes in response to ventricular and atrial wall stress and serve as serum biomarkers for the diagnosis of heart failure [1].

Besides their established role in patients with heart failure, several studies have described the powerful prognostic role of natriuretic peptides for prediction of cardiovascular outcomes in asymptomatic cohort-studies [2–6].

Natriuretic peptides are increased in subjects with early stages of cardiac diseases such as diastolic dysfunction, left ventricular...
hypertrophy, and silent myocardial ischemia with plasma-levels markedly below the cut-off value used for the diagnosis of heart failure [4,7]. Thus, natriuretic peptides seem to reflect pancardiac functional heart disease also in early asymptomatic stages and thus may hereafter be useful in cardiac screening programs [4,7].

However, there is a lack of studies investigating the association of NT-proBNP levels with cardiac events in a large cohort from primary care setting.

Therefore, aim of this analysis was to determine the association of NT-proBNP with all-cause mortality and cardiovascular mortality above traditional risk factors in a prospective cohort study of unselected elderly patients in a representative primary care setting in Germany (getABI Study).

2. Methods

2.1. Participants

The German Epidemiological Trial on Ankle Brachial Index (getABI) is a prospective observational cohort study initiated in October 2001. Details about recruitment and study design have been previously published [8]. In brief, 34 vascular physicians trained and supervised 344 physicians throughout Germany. Patients were included in a prespecified week in October 2001 regardless of seeing the doctor. In total, 6880 elderly (>65 years) patients were recruited. Each practice included an average of 20 patients, the only exclusion criteria was life expectancy less than 6 month as judged by the doctor. At baseline, a medical history assessment including prescribed medications, physical examination, and blood sampling were performed. Follow-up included physician visits at one, three, five and seven years after baseline.

2.2. Measurement of NT-proBNP

Subjects blood samples were collected at baseline. NT-proBNP was determined using a chemoluminescent microparticle immunoassay (CMIA, Abbott Diagnostics, Chicago, Illinois, USA) on an Abbott Architect i2000SR analyzer. Interassay CVs were 2.8% and 2.3% at mean values of 153 and 4849 pg/ml.

NT-proBNP was categorized into 3 levels as clinically established thresholds: minimum up to 125, 125 to 300, and>300 (unit pg/ml) [9]. GetABI participants with missing NT-proBNP values were excluded. Thus, 6382 patients comprised the analysis population for this work.

2.3. Cardiovascular diseases and endpoint definition

Cardiovascular diseases (CVDs) at baseline were defined as myocardial infarction, stroke, coronary revascularization, or revascularization of the carotid arteries. The endpoints death and death from cardiovascular cause were considered if declared by the physician (CRF) or via death certificate. If possible, they were verified by clinical reports. For lost to follow-up participants the registration office was asked for living status. Death from Cardiovascular cause comprised fatal myocardial infarction and cerebrovascular events.

2.4. Statistical analysis

On basis of the pre-determined NT-proBNP categories, characteristics of participants are presented descriptively with mean and standard deviations for continuous variables and counts and proportions for categorical variables. Survival analyses were done by means of Kaplan-Meier plots for the univariable analysis according to NT-proBNP categories, and by Cox proportional hazards regression for the adjusted models. Variables for adjustment of hazards were selected from previously published work of the getABI study group [10,11]. The Missing values for predictor variables were imputed by randomly selected values from the cohort. Results for predictors are given as hazard ratios (HR) and 95% confidence intervals (CI). Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, North Carolina, USA).

3. Results

3.1. Baseline characteristics

A total of 6382 patients were included (mean age 72.5 ± 5.3, 42.2% female) in this analysis. The median NT-proBNP level was 143.15 pg/ml (Q1: 83.6; Q3: 271.8). In average, NT-proBNP levels were higher in male patients compared to female (304.6 pg/ml vs. 271.7 pg/ml).

The baseline characteristics were depicted in Table 1 stratified for NT-proBNP using 125 and 300 pg/ml as threshold [9].

3.2. Association of NT-proBNP with all-cause mortality and cardiovascular mortality

After a follow-up time of 41,873 person-years 1204 participants died from any cause and 347 patients had a fatal cardiovascular event.

The incidence of all-cause and cardiovascular mortality was higher in subjects with higher levels of NT-proBNP (all-cause mortality/cardiovascular mortality: 35.4%/13.6% for NT-proBNP > 300 pg/ml; 16.2%/4.0% for NT-proBNP 125–300 pg/ml vs. 11.4%/2.4% for NT-proBNP ≤ 125 pg/ml).

Table 2a and 2b show the Cox-regression analysis for all-cause mortality and fatal cardiovascular events. Unadjusted, subjects with a NT-proBNP level > 300 pg/ml had more than three-fold risk for all-cause mortality and more than six-fold increased risk for cardiovascular mortality. Associations were attenuated but remained statistically significant after further adjustment for age, sex, traditional risk factors, cardiac diseases and cardiac medications using NT-proBNP as continuous variable as well as using the defined thresholds. After further adjustment (full model) for cardiac diseases and cardiac medications associations remained unchanged as depicted in Table 3. In particular, when modelling NT-proBNP as a continuous variable, a 2-fold increase of it was associated with a 50% increase in the risk of cardiovascular death in the model M5. The ability of the model M5 to distinguish between alive and death was good, since the area under the curve (AUC) was determined as 0.77.

Further, we investigated if the associations between continuous NT-proBNP and endpoints were modified by sex. Regarding all-cause mortality, in females a one-unit change in log2-transformed NT-proBNP resulted in elevation of the hazard by 38.9%, and for men by 26.7% (p-value for interaction 0.015 in fully adjusted model), whereas for cardiovascular mortality, although hazards were still numerically different, that interaction was not significant (p-value 0.39, results not shown).

Fig. 1 displays the survival probability according to NT-proBNP levels, showing a significant difference in mortality rate in patients with a NT-proBNP level > 300 pg/ml.

4. Discussion

In this large prospective cohort study we examined the association of NT-proBNP with all-cause and cardiovascular mortality above traditional risk factors.
Increased NT-proBNP levels were associated with excessive prevalence of all-cause and cardiovascular mortality, resulting in an overall mortality of 35.4% and cardiovascular mortality of 13.6% in 7 years for patients with a NT-proBNP level > 300 pg/ml. The associations remained statistically significant after adjustment for traditional risk factors, cardiac diseases and medications.

Our results show strong associations of higher NT-proBNP levels with mortality in an unselected, large population of elderly patients in the primary care setting independent of traditional risk factors. Our results suggest that the mechanism involved in event manifestation and that are reflected in elevated NT-proBNP levels, are different from those mediated through traditional risk factors. Natriuretic peptides are commonly used for the diagnosis of heart failure in symptomatic patients with dyspnoea. Moreover, it was showed, that natriuretic guided treatment for chronic heart failure improves mortality. [12]

However, there is growing evidence, that higher levels of natriuretic peptides predict cardiac events and mortality in the general population and therefore serve as markers of cardiovascular risk.

---

**Table 1**

Baseline characteristics.

|          | Overall | NT-proBNP ≤ 125 pg/ml | NT-proBNP 125–300 pg/ml | NT-proBNP > 300 pg/ml |
|----------|---------|-----------------------|-------------------------|-----------------------|
| N        | 6382    | 2780                  | 2190                    | 1412                  |
| Age (years) | 72.51 (5.27) | 71.23 (4.76) | 72.71 (5.17) | 74.68 (5.64) |
| Males (%) | 2693 (42.20%) | 1316 (47.34%) | 763 (34.84%) | 614 (43.48%) |
| Education: ISCED < 3 (%) | 1586 (24.85%) | 634 (22.81%) | 576 (26.30%) | 376 (26.63%) |
| Current Smoker (%) | 3579 (9.06%) | 1624 (58.42%) | 1458 (66.58%) | 114 (8.07%) |
| Systolic blood pressure (mmHg) | 1257 (19.70%) | 317 (11.40%) | 1499 (23.49%) | 762 (54.37%) |
| Diastolic blood pressure (mmHg) | 1257 (23.99%) | 667 (23.99%) | 482 (22.15%) | 411 (29.11%) |
| Vitamin D < 50 ng/ml (%) | 1560 (24.44%) | 667 (23.99%) | 482 (22.15%) | 411 (29.11%) |
| Diabetes (%) | 1319 (20.67%) | 414 (14.89%) | 468 (21.37%) | 437 (30.95%) |
| Arterial hypertension (%) | 1626 (25.48%) | 716 (25.76%) | 487 (22.24%) | 636 (45.04%) |
| LDL-C > 130 mg/dl (%) | 2736 (42.87%) | 1309 (47.09%) | 928 (42.37%) | 499 (35.34%) |
| GFR < 60 ml/min (%) | 1935 (30.32%) | 516 (18.56%) | 743 (33.93%) | 676 (47.88%) |
| Lipid-lowering medication (%) | 1786 (27.98%) | 626 (22.52%) | 584 (26.67%) | 576 (40.79%) |
| Digitalis (%) | 516 (8.09%) | 140 (6.39%) | 263 (18.63%) | 293 (21.11%) |
| Antihypertensive medication (%) | 2468 (38.67%) | 1009 (36.29%) | 823 (37.58%) | 636 (45.04%) |
| CRP > 3 mg/L (%) | 2468 (38.67%) | 1009 (36.29%) | 823 (37.58%) | 636 (45.04%) |
| HCY > 15 μmol/L (%) | 3188 (49.95%) | 1247 (44.86%) | 1072 (48.95%) | 869 (61.54%) |
| GFR < 60 ml/min (%) | 1586 (24.85%) | 634 (22.81%) | 576 (26.30%) | 376 (26.63%) |
| Males (%) | 2693 (42.20%) | 1316 (47.34%) | 763 (34.84%) | 614 (43.48%) |
| Age (years) | 72.51 (5.27) | 71.23 (4.76) | 72.71 (5.17) | 74.68 (5.64) |
| N 6382 | 2780 | 2190 | 1412 |

ISCED: International Standard Classification of Education; CRP: C-reactive protein; GGT: Gamma-Glutamyl Transferase; HCY: Homocystein; PAD: peripheral artery disease; LDL: Low density lipoprotein; GFR: Glomerular filtration rate; HDL: High density lipoprotein.

**Table 2a**

Cox regression for the association of NT-proBNP with all-cause mortality.

| Model | Hazard Ratio (95%-CI) | Hazard Ratio (95%-CI) | Hazard Ratio (95%-CI) |
|-------|-----------------------|-----------------------|-----------------------|
| Unadjusted | 1.51 (1.46; 1.57) | 1.41 (1.35; 1.46) | 1.43 (1.32; 1.43) |
| Model 1 (Age and gender) | 1.43 (1.23; 1.67) | 2.74 (2.35; 3.19) | 3.09 (2.67; 3.56) |
| Model 2 (Model 1 + Cardiac medication) | 1.43 (1.31; 1.42) | 2.64 (2.26; 3.08) | 3.09 (2.67; 3.56) |
| Model 3 (FRV) | 1.43 (1.38; 1.49) | 2.64 (2.26; 3.08) | 3.09 (2.67; 3.56) |
| Model 4 (model 2 + Cardiac diseases) | 1.36 (1.26; 1.37) | 2.34 (1.99; 2.74) | 3.09 (2.67; 3.56) |
| Model 5 (Full adjusted model) | 1.36 (1.26; 1.37) | 2.34 (1.99; 2.74) | 3.09 (2.67; 3.56) |

Cardiac diseases: cardiovascular diseases including coronary heart diseases, cerebral diseases and peripheral artery diseases. Cardiac medication including beta-blocker, diuretics and digitalis.

**Table 2b**

Cox regression for the association of NT-proBNP with Cardiovascular mortality.

| Model | Hazard Ratio (95%-CI) | Hazard Ratio (95%-CI) | Hazard Ratio (95%-CI) |
|-------|-----------------------|-----------------------|-----------------------|
| Unadjusted | 1.51 (1.46; 1.57) | 1.41 (1.35; 1.46) | 1.43 (1.32; 1.43) |
| Model 1 (Age and gender) | 1.43 (1.23; 1.67) | 2.74 (2.35; 3.19) | 3.09 (2.67; 3.56) |
| Model 2 (Model 1 + Cardiac medication) | 1.43 (1.31; 1.42) | 2.64 (2.26; 3.08) | 3.09 (2.67; 3.56) |
| Model 3 (FRV) | 1.43 (1.38; 1.49) | 2.64 (2.26; 3.08) | 3.09 (2.67; 3.56) |
| Model 4 (model 2 + Cardiac diseases) | 1.36 (1.26; 1.37) | 2.34 (1.99; 2.74) | 3.09 (2.67; 3.56) |
| Model 5 (Fully adjusted model) | 1.36 (1.26; 1.37) | 2.34 (1.99; 2.74) | 3.09 (2.67; 3.56) |

Cardiac diseases: cardiovascular diseases including coronary heart diseases, cerebral diseases and peripheral artery diseases. Cardiac medication including beta-blocker, diuretics and digitalis.
Wang et al. reported an association of BNP with all-cause mortality and cardiovascular events in a healthy population [3]. These results were confirmed in a meta-analysis with 87,747 subjects showing a 3-fold risk for cardiovascular events in subjects with a higher level of natriuretic peptides [13]. Another work of McKie et al including 2042 individuals showed that NT-proBNP independently predicted mortality and heart failure in the general population free of overt heart failure [14]. In another meta-analysis, recently published, on 25,715 subjects, elevated NT-proBNP levels appeared to be independently associated with increased risk for cardiovascular and all-cause mortality in the general population [15]. Participants in the highest NT-proBNP concentration had a significantly increased 3.77 fold cardiovascular mortality and 2.44 fold all-cause mortality, even after adjustment for traditional risk factors. In this setting, authors stated that higher NT-proBNP levels might reflect the degree of systemic atherosclerosis and/or an unknown initial cardiac overload.

Other studies demonstrated the prognostic value of natriuretic peptides in different settings:

Table 3
Predictors of all-cause mortality in the fully adjusted model, multivariable analysis.

| Risk factor                          | Hazard-Ratio | 95% CI       |
|--------------------------------------|--------------|--------------|
| Age (per year)                       | 1.062        | 1.05–1.08    |
| Sex                                  | 1.983        | 1.74–2.26    |
| NT proBNP 125–300 pg/ml              | 1.363        | 1.17–1.59    |
| NT proBNP > 300 pg/ml                | 2.335        | 1.99–2.74    |
| Hypertension                         | 0.518        | 0.80–1.05    |
| Diabetes mellitus                    | 1.445        | 1.27–1.64    |
| Smoker (current)                     | 2.027        | 1.72–2.39    |
| LDL (>130 mg/dL)                     | 0.806        | 0.71–0.91    |
| Lipid-lowering medication            | 0.722        | 0.62–0.84    |
| CVD                                  | 1.267        | 1.09–1.47    |
| ISCED 0–2 vs. 3–6                    | 1.279        | 1.11–1.48    |
| CRP (>3 mg/l)                        | 1.186        | 1.05–1.33    |
| GGT (>Q3)                            | 1.302        | 1.14–1.48    |
| GFR (per 10 ml/min/1.73 m²)          | 0.923        | 0.89–0.95    |
| Homocystein (>15 µmol/l)             | 1.171        | 1.04–1.32    |
| Vitamin D (>50 nmol/l)               | 1.398        | 1.21–1.61    |
| PAD                                  | 1.389        | 1.22–1.58    |
| Use of Diuretics                     | 1.220        | 1.07–1.39    |
| Use of Beta blocker                  | 0.836        | 0.73–0.96    |
| Use of Digitalis                     | 1.360        | 1.15–1.61    |

LDL: Low density lipoprotein; CVD: cardiovascular diseases; ISCED: International Standard Classification of Education; CRP: C-reactive protein; GGT: Gamma-Glutamyl Transferase; PAD: peripheral artery disease; LDL: Low density lipoprotein; GFR: Glomerular filtration rate; HDL: High density lipoprotein.

Bibbings et al. showed, that elevated levels of NT-proBNP predict cardiovascular morbidity and mortality in patients with stable coronary heart disease independent of systolic and diastolic function assessed by echocardiography [16]. Paniagua et al. demonstrated the prognostic value of natriuretic peptide in dialysis patients. [17] and Tu et al. showed that NT-proBNP may be useful as independent prognostic markers in patients with ischemic stroke [18].

NT-proBNP is strongly associated with all-cause mortality also in hypertensive population. Paget et al. have demonstrated that plasma NT-proBNP levels ≥ 133 pg/ml were associated with a threefold increase of the risk of death in comparison with levels < 50.8 pg/ml even after adjustment for confounders. Moreover, NT-proBNP resulted to be a stronger prognostic marker than ECG and its dosage has been proposed as first test for the cardiovascular stratification instead of ECG [19].

In our previously published work we demonstrated an association of BNP with coronary events and all-cause mortality, with BNP significantly improving prediction of risk in the general population above and complementary to coronary artery calcification and traditional risk factors [2]. For the risk prediction in the general population it was suggested that BNP reflects early stages of systolic and diastolic dysfunction; additionally it was hypothesized that BNP is linked with asymptomatic chronic cardiac ischemia. These suggestions were confirmed in a recently published study showing that BNP screening - in asymptomatic treated primary prevention patients - is able to identify existing left ventricular hypertrophy, systolic and diastolic dysfunction, left atrial enlargement, and ischemia [7].

As a conclusion, it has been suggested, that BNP may reflect “pancardiac” damage in early stages and that measurements of BNP may help to identify those who need closer examination and further risk stratification [20].

Our here presented data revealed that elevated NT-proBNP levels in the primary care setting are able to identify patients at high risk for a future cardiac event.

4.1. Clinical Implications

In our study we describe a significant association of NT-proBNP with fatal cardiac events and all-cause mortality, suggesting that NT-proBNP is the first biomarker which may improve risk prediction independent of and complementary to traditional cardiovascular risk factors. Together with previously published results, these data suggest that NT-proBNP may improve risk discrimination for cardiac events above and beyond traditional cardiovascular risk factors and therefore may help to identify subjects that may profit from aggressive risk modification. Furthermore, subjects with higher NT-proBNP levels may benefit from a cardiological workup for detections of early stages of a systolic or diastolic heart dysfunction even in the absence of symptoms.

We emphasize that assessment of NT-proBNP is feasible using a simple blood.

5. Conclusion

In our study we describe a significant association of NT-proBNP with fatal cardiovascular events and all-cause mortality, suggesting that NT-proBNP is the first biomarker which may improve risk prediction independent of traditional cardiovascular risk factors.

6. Limitations

A limitation of our study is that we did not perform an echocardiography at baseline to get more information and reasons for...
elevated levels of NT-proBNP as heart failure. We presented heart failure medications and we included heart failure medication into Cox proportional hazard analyses.

Furthermore, our study includes the measurement of NT-proBNP only, not of BNP.

CRediT authorship contribution statement

Henrik Rudolf: Conceptualization, Methodology, Software, Writing - original draft. Andreas Mügge: Writing - review & editing, Supervision. Hans J. Trampisch: Investigation, Writing - review & editing, Supervision. Hubert Scharnagl: Investigation, Supervision. W. März: Investigation, Supervision. Kaffer Kara: Supervision, Conceptualization, Methodology, Software, Writing - original draft.

Acknowledgements

The authors thank Abbott GmbH & Co. KG for providing NT-proBNP assays for this project without charge. The study was supported by a grant from Sanofi-Aventis Deutschland GmbH; the sponsor was not involved in the design and conduct of the project, in the analysis and interpretation of the data, and in preparation or approval of the manuscript.

The authors thank Lusik Balayan and Sabine Paulitsch for the technical assistance.

Declaration of Competing Interest

The authors report no relationships that could be construed as a conflict of interest.

References

[1] A.S. Maisel, P. Krishnaswamy, R.M. Nowak, et al., Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N. Engl. J. Med. 347 (2002) 161–167.
[2] K. Kara, A.A. Mahabadi, M.H. Berg, et al., Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study, Eur. J. Prev. Cardiol. 21 (2014) 1171–1179.
[3] T.J. Wang, M.G. Larson, D. Levy, et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death, N. Engl. J. Med. 350 (2004) 655–663.
[4] K. Kara, A.A. Mahabadi, M.H. Geisel, et al., B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events-The Heinz Nixdorf Recall Study, Clin. Res. Cardiol. 103 (2014) 125–132.
[5] K. Kara, J. Gronewold, T. Neumann, et al., B-type natriuretic peptide predicts stroke of presumable cardioembolic origin in addition to coronary artery calcification, Eur. J. Neurol. 21 (2014) 914–921.

A.S. Maisel, P. Krishnaswamy, R.M. Nowak, et al., Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, N. Engl. J. Med. 347 (2002) 161–167.

[7] M.A. Nadir, S. Rehbaz, L. Wei, et al., Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease, J. Am. Coll. Cardiol. 60 (2012) 960–968.

[8] C. Diehm, getABI Study Group, getABI: German epidemiological trial on ankle brachial index for elderly patients in family practice to detect peripheral arterial disease, significant marker for high mortality, Vasa 31 (2002) 241–248.

[9] Piotr Ponikowski, Adrian A. Voors, Stefan D. Anker, Héctor Bueno, John G.F. Cleland, Andrew J.S. Coats, Volkmart Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A. Jankowska, Marielli Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T. Pifariss, Burkert Pieske, Jillian P. Riley, Giuseppe M.C. Rosano, Luis M. Ruispolo, Frank Ruschitzka, Frans H. Rutten, Peter van der Meer, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur. Heart J. 37 (27) (2016) 2129–2200, https://doi.org/10.1093/eurheartj/ehw128.

[10] C. Diehm, J.R. Allenberg, D. Pittrow, et al., Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease, Circulation 120 (2009) 2053–2061, https://doi.org/10.1161/CIRCULATIONAHA.109.965600, Epub 2009 Nov 9.

[11] F. Kreutzer, D. Krause, R. Klaassen-Mielke, H.J. Trampisch, C. Diehm, H. Rudolf, Gamma-glutamyl transferase as a risk factor for mortality and cardiovascular events in older adults results from a prospective cohort study in a primary care setting (getABI), Vasa. 48 (2019) 311–319, https://doi.org/10.1024/0301-1526/a000796, Epub 2019 Apr 17.

[12] G.J. Lainchbury, R.W. Troughton, K.M. Strangman, C.M. Fampston, A. Pilbrown, T. G. Yandle, A.K. Hamid, M.G. Nicholls, A.M. Richards, N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial, J. Am. Coll. Cardiol. 55 (1) (2009 Dec 29) 53–60, https://doi.org/10.1016/j.jacc.2009.02.095.

[13] E. Di Angelantonio, R. Chowdhury, N. Sarwar, et al., B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies, Circulation 120 (2009) 2177–2187.

[14] P.M. McKie, A. Cataliotti, J.S. Sangaralingham, et al., Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study, Mayo Clin. Proc. 86 (2011) 1154–1160.

[15] Z. Geng, L. Huang, M. Song, Y. Song, N-terminal pro-brain natriuretic peptide and cardiovascular or all-cause mortality in the general population: a meta-analysis, Sci. Rep. 7 (2017) 41504.

[16] K. Bbibins-Domingo, R. Gupta, B. Na, et al., N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease, JAMA 297 (2) (2007 Jan 10) 169–176.

[17] R. Paniagua, M.D. Ventura, M. Avila-Diaz, et al., NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients, Nephrol. Dial. Transplant. 25 (2) (2010 Feb) 551–557, https://doi.org/10.1093/ndt/gfp395, Epub 2009 Aug 12.

[18] W.J. Tu, G.Z. Ma, Y. Ni, et al., Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke, Neurology. 88 (20) (2017 May 16) 1899–1905.

[19] V. Paget, L. Legedz, N. Gaudebout, et al., N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension, Hypertension. 57 (2011) 702–709.

[20] A. Struthers, C. Lang, The Potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent ‘pancardiac’ target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney, Eur. Heart J. 28 (2007) 1678–1682, Epub 2007 Jun 14.